News
4h
Zacks Investment Research on MSNCan Keytruda Sustain Merck's Growth Through the Rest of 2025?
Merck’s MRK strong foothold in the oncology space is propelled by its biggest revenue driver, Keytruda. The blockbuster PD-L1 inhibitor alone accounted for more than 50% of the company’s ...
After having his medical license revoked in California, a doctor sought escape in Montana. Now, he's suing the CDC for its childhood vaccine policies, which he calls unconstitutional.
Covid-era coercion and misinformation bred public distrust, but the vaccines did save countless lives.
Scientists say HHS’ decision to defund mRNA vaccine research will leave the country less prepared for pandemics, and make it ...
Illinois researchers, including some working on vaccines for cancer and rare diseases, worry the federal government turning ...
With that in mind, let's consider two stocks that people in their 30s -- who are still a good distance away from retirement - ...
Showing that his loyalty to his own anti-vax mentality is greater than his loyalty to President Donald Trump, Robert F. Kennedy Jr., the dangerous quack atop the Department of Health and Human ...
The S&P 500 slipped 0.3% on Friday, Aug. 15, 2025, as a report on consumer sentiment revealed growing concerns about tariff ...
The Nobel Prize-winning technology underpinning COVID-19 vaccines is also fueling a host of biotechs developing treatments ...
The average short interest in the S&P 500 Health Care Index Sector (XLV) dipped slightly in July to 1.95% from 1.96% in June.
RFK Jr. canceled nearly $500 million in mRNA vaccine research funding. Plus, the latest climate news, from flooding in Alaska ...
Scientists say HHS’s decision to stop investing in mRNA vaccine research is another sign of the growing politicization of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results